<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192826</url>
  </required_header>
  <id_info>
    <org_study_id>8393 / 26- 4- 2016</org_study_id>
    <nct_id>NCT03192826</nct_id>
  </id_info>
  <brief_title>Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy</brief_title>
  <official_title>Study of the Efficacy of Brinzolamide 1% Plus Brimonidine 0.2% Versus Brimonidine 0.2% in the Prevention of Intraocular Pressure Rise After Nd-YAG Laser Capsulotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Patras</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of a Brinzolamide/Brimonidine fixed combination (FC) with Brimonidine
      0.2% in preventing intraocular pressure (IOP) elevations after neodymium:
      yttrium-aluminum-garnet (Nd:YAG) laser posterior capsulotomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective, randomized, double masked clinical trial, patients scheduled to undergo
      Nd:YAG laser posterior capsulotomy for posterior capsule opacification are randomized in 3
      groups. The Brimonidine group receives 1 drop of Brimonidine 0.2%. The
      Brinzolamide/Brimonidine group receives 1 drop of Brinzolamide 1%/Brimonidine 0.2% fixed
      combination. The Control group receives artificial tears. All groups are administered a
      single drop instillation, approximately one hour before Nd:YAG application. Intraocular
      pressure measurements are performed before treatment (baseline) and at the 1, 3, 24 hours and
      1 week post treatment.

      Dexamethasone ophthalmic drops are prescribed q.i.d. for one week after the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2016</start_date>
  <completion_date type="Actual">July 8, 2017</completion_date>
  <primary_completion_date type="Actual">July 8, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, randomized, double masked comparative study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Patients are masked to their assignment by covering the labels on the bottles of the drugs administered The investigator responsible for the measurement of the intraocular pressure is also masked to the intervention administered to each patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (IOP) 1 hour after Nd-YAG capsulotomy</measure>
    <time_frame>Measurement of IOP 1 hour after the procedure</time_frame>
    <description>Measurement of IOP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure(IOP) 3 hours after Nd-YAG capsulotomy</measure>
    <time_frame>Measurement of IOP 3 hours after the procedure</time_frame>
    <description>Measurement of IOP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure(IOP) 24 hours after Nd-YAG capsulotomy</measure>
    <time_frame>Measurement of IOP 24 hours after the procedure</time_frame>
    <description>Measurement of IOP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure(IOP) 1 week after Nd-YAG capsulotomy</measure>
    <time_frame>Measurement of IOP 1 week after the procedure</time_frame>
    <description>Measurement of IOP</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Posterior Capsule Opacification</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Brinzolamide/Brimonidine FC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine 0.2%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial tears</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 drop of artificial tears 1 hour before Nd-YAG capsulotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide/Brimonidine FC</intervention_name>
    <description>1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy</description>
    <arm_group_label>Brinzolamide/Brimonidine FC</arm_group_label>
    <other_name>SIMBRINZA (brinzolamide/brimonidine 1%/0.2%), Alcon Lab. Ltd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine 0.2%</intervention_name>
    <description>1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy</description>
    <arm_group_label>Brimonidine 0.2%</arm_group_label>
    <other_name>ALPHAGAN (brimonidine tartrate 0.2%) Allergan Pharm. Ltd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artificial tears</intervention_name>
    <description>1 drop of artificial tears 1 hour before Nd-YAG capsulotomy</description>
    <arm_group_label>Artificial tears</arm_group_label>
    <other_name>TEARS NATURALE EY.DRO.SOL 0.1%+0.3% Alcon Laboratories Ltd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients scheduled to undergo laser posterior capsulotomy due to posterior capsule
             opacification (PCO) after uneventful phacoemulsification cataract extraction with
             implantation of posterior chamber intraocular lenses (IOL/PC).

        Exclusion Criteria:

          -  baseline IOP greater than 21mmHg

          -  glaucomatous eyes, already under treatment with anti glaucomatic medications

          -  intraocular surgery except for uncomplicated cataract surgery

          -  previous photorefractive surgery

          -  active ocular inflammation or infection

          -  patients under systemic administration of medications known to affect IOP

          -  patients with severe respiratory or cardiovascular disease

          -  pregnant or breast feeding women, and individuals with known hypersensitivity or
             contraindication for administration of the medications tested

          -  a measurement of IOP &gt; 30 mmHg at any time point of the study, or an increase from
             baseline &gt;20 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantinos Georgakopoulos, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <state>Achaia</state>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>July 8, 2017</last_update_submitted>
  <last_update_submitted_qc>July 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Patras</investigator_affiliation>
    <investigator_full_name>Constantinos D. Georgakopoulos, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD, Associate Professor of Ophthalmology, Univerisity of Patras</investigator_title>
  </responsible_party>
  <keyword>Nd-YAG capsulotomy</keyword>
  <keyword>ocular hypertension</keyword>
  <keyword>brimonidine</keyword>
  <keyword>brinzolamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

